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Regulatory T cells (Tregs) play an indispensable role in maintaining immunological unresponsiveness 
to self-antigens and in suppressing excessive immune responses deleterious to the host. Tregs are 
produced in the thymus as a functionally mature subpopulation of T cells and can also be induced 
from naive T cells in the periphery. Recent research reveals the cellular and molecular basis of Treg 
development and function and implicates dysregulation of Tregs in immunological disease.Introduction
The mammalian immune system protects the host from a broad 
range of pathogenic microorganisms while avoiding misguided 
or excessive immune reactions that would be deleterious to 
the host. Both protective and harmful immune responses are 
principally mediated by T and B cells, which possess enor-
mous diversity in antigen recognition, high antigen specificity, 
potent effector activity, and long-lasting immunologic memory. 
Because of this potency, serious damage to the host may ensue 
if aberrant immune responses, such as autoimmunity or allergy, 
are triggered. A major challenge in immunology and medicine 
is to determine how unresponsiveness of the adaptive immune 
system to self-antigens (that is, immunological self-tolerance) 
is established and maintained, and how the quality and mag-
nitude of adaptive immune responses to non-self-antigens are 
controlled so as to avoid damage to the host. Understanding 
the mechanisms of immunological self-tolerance will also pro-
vide insights into how weak immune responses, such as those 
against tumor antigens in cancer patients or against microbial 
antigens in chronic infection, can be augmented, or conversely, 
how strong immune responses such as graft rejection can be 
restrained.
There are two types of mechanisms, “recessive” and “domi-
nant,” for achieving self-tolerance and immune homeostasis. In 
the recessive mechanisms of self-tolerance, the fate of antigen-
exposed self-reactive lymphocytes is determined in a cell-intrin-
sic manner. For example, some lymphocytes are programmed 
to die by apoptosis when exposed to self-antigen at an imma-
ture stage of their development in the central generative organs 
(the thymus for T cells and the bone marrow for B cells). Other 
lymphocytes may replace self-reactive T cell or B cell receptors 
(TCRs and BCRs, respectively) with nonreactive ones, a process 
called receptor editing. Those that have escaped clonal dele-
tion and receptor editing may further mature but can be ren-
dered anergic (functionally inactivated) upon exposure to self-
antigen. In addition, their activation thresholds may be raised 
by the expression of inhibitory receptors or negative signaling 
molecules or they may not survive long because of activation-
induced cell death. The cell-intrinsic control of cell fate or acti-
vation threshold also contributes to the inhibition of excessive 
immune responses to non-self-antigens.In the dominant or cell-extrinsic mechanism, certain T cells 
actively keep in check the activation and expansion of aber-
rant or overreactive lymphocytes, in particular other types 
of T cells. Until recently, the physiological significance, and 
even the existence of T cell-mediated immune suppression, 
has been highly contentious. Yet there is now firm evidence 
that the normal immune system produces a population of T 
cells, called regulatory T cells (Tregs), that are specialized for 
immune suppression. Disruption in the development or func-
tion of Tregs is a primary cause of autoimmune and inflam-
matory diseases in humans and animals. Moreover, it is now 
emerging that every adaptive immune response involves 
recruitment and activation of not only effector T and B cells 
but also Tregs, and that the balance between the two popula-
tions is critical for the proper control of the quality and mag-
nitude of adaptive immune responses and for establishing or 
breaching tolerance to self- and non-self-antigens.
In this Review, we discuss the roles of Tregs in self-toler-
ance and immune homeostasis, the cellular and molecular 
basis of their development and function, and how they might 
be exploited at the cellular and molecular levels to control 
a wide spectrum of physiological and pathological immune 
responses.
Thymus-Derived Tregs
It has been known for nearly 40 years that simple manipulation 
of the thymus and T cells, but not self-antigen, can produce 
autoimmune disease in normal animals (reviewed in Sakaguchi, 
2000). Neonatal thymectomy at a critical period (around day 3 
after birth) of selected strains of normal mice results in auto-
immune damage of various organs (such as the thyroid, stom-
ach, ovaries, and testes) and the appearance of tissue-specific 
autoantibodies in the circulation. Adult thymectomy of selected 
strains of normal rats followed by several rounds of sublethal 
X-irradiation produces autoimmune thyroiditis and type I diabe-
tes. Importantly, inoculation of normal T cells, in particular CD4+ 
T cells or CD4+CD8− thymocytes, from untreated syngeneic 
animals inhibits the development of autoimmunity (Sakaguchi 
et al., 1982; Fowell and Mason, 1993). These results indicated 
that normal animals harbor not only potentially pathogenic self-
reactive T cells but also T cells that suppress autoimmunity, with Cell 133, May 30, 2008 ©2008 Elsevier Inc. 775
Figure 1. Effects of Treg Deficiency in Mice and Humans
(A) T cell suspensions prepared from normal mice can be depleted of CD25+CD4+ regulatory T cells (Treg) and transferred to syngeneic T cell-deficient mice 
(such as athymic nude mice). The recipient mice spontaneously develop autoimmune disease and inflammatory bowel disease and reject tumor cells. By con-
trast, when CD25+CD4+ Tregs are enriched from normal mice and transferred, the recipient nude mice accept allogeneic skin grafts. 
(B) Male children are afflicted with IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). Mothers bear heterozygous defects of 
the FOXP3 gene and either have reduced numbers of normal Tregs or are mosaic for normal Tregs and functionally defective Tregs because of random inactiva-
tion of the X chromosome. Blue- and yellow-colored circles indicate intact Tregs and effector T cells (Teff), respectively. Dotted circles indicate dysfunctional 
Tregs (or the absence of Tregs). 
(C) The normal thymus produces Foxp3-expressing natural Tregs. Tregs mainly suppress the development of effector T cells from naive T cells.the latter dominantly controlling the former. A critical experi-
ment to prove this interpretation was to identify autoimmune-
suppressive T cells using a definitive phenotypic marker and to 
determine whether removal of the population from normal adult 
animals disrupts self-tolerance and leads to autoimmune dis-
ease. Indeed, when CD4+ T cell suspensions from the spleens of 
normal mice or rats were depleted of cells bearing a particular 
marker profile (CD5high or CD45RClow) ex vivo, and the remaining 
CD4+ T cells were transferred to syngeneic T cell-deficient athy-
mic nude mice or rats, the recipients spontaneously developed 
autoimmune disease in multiple organs within a few months 
(Sakaguchi et al., 1985; Powrie and Mason, 1990) (Figure 1A). 
Reconstitution of the depleted CD4+ T cell subpopulation inhib-
ited autoimmunity. Subsequent efforts to search for a more 
specific marker with which to delineate the putative autoim-
mune-preventive CD4+ T cells revealed the CD25 molecule (the 
IL-2 receptor α chain) as a candidate (Sakaguchi et al., 1995). 
Transfer of T cell suspensions depleted of CD25+ T cells indeed 
produces autoimmune disease in athymic nude mice, whereas 
cotransfer of a small number of CD25+CD4+ T cells clearly inhib-
its the development of autoimmunity.
Notably, depletion of naturally arising Tregs not only elic-
its autoimmunity but also augments immune responses to 
non-self-antigens. Treg depletion produces inflammatory 
bowel disease, which likely results from excessive immune 
responses to commensal bacteria in the intestine (Singh et 
al., 2001). Removal or reduction of CD25+CD4+ Tregs also pro-
vokes effective tumor immunity in otherwise nonresponding 
animals and augments microbial immunity in chronic infec-
tion, leading to eradication of tumors or microbes, respec-
tively (reviewed in Wang and Wang, 2007; Belkaid and Rouse, 
2005). Conversely, CD25+CD4+ T cells enriched from normal 776 Cell 133, May 30, 2008 ©2008 Elsevier Inc.mice suppress allergy, establish tolerance to organ grafts, 
prevent graft-versus-host disease after bone marrow trans-
plantation, and promote feto-maternal tolerance (reviewed in 
Sakaguchi, 2005) (Figure 1A).
CD25+CD4+ Tregs are also present in the periphery of 
humans (reviewed in Baecher-Allan et al., 2004). T cells that 
are reactive with a particular self-antigen targeted in auto-
immune disease (such as glutamic acid decarboxylase in 
type I diabetes) or a tumor-associated antigen can be easily 
expanded in vitro from peripheral blood of normal healthy 
individuals when T cells are stimulated with self or tumor 
antigen after depletion of CD25+CD4+ Tregs (Danke et al., 
2004).
With these findings, it is possible to formulate several key 
notions concerning dominant self-tolerance and immune 
regulation. First, the normal immune system generates 
CD25+CD4+ Tregs that are engaged in suppressing immune 
responses toward self, quasi-self (such as autologous tumor 
cells), and non-self (such as microbes and allografts). Sec-
ond, the normal thymus produces potentially pathogenic self-
reactive T cells as well as functionally mature Tregs; mature 
Tregs persist in the periphery and exert dominant control over 
the self-reactive T cells. Third, Treg deficiency in the periph-
ery is sufficient to evoke chronic T cell-mediated autoimmu-
nity and immunopathology.
Foxp3 Controls Treg Development and Function
Naturally occurring Tregs specifically express the transcrip-
tion factor Foxp3 (forkhead box P3), a member of the fork-
head/winged-helix family of transcription factors. Foxp3 is 
a master regulator of Treg development and function. The 
Foxp3 gene was first identified as the defective gene in the 
mouse strain Scurfy. Surfy is an X-linked recessive mutant 
that is lethal in hemizygous males within a month after birth, 
exhibiting hyperactivation of CD4+ T cells and overproduction 
of proinflammatory cytokines (Brunkow et al., 2001). Muta-
tions of the human gene FOXP3 are the cause of the genetic 
disease IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked syndrome), which is the human coun-
terpart of Scurfy (reviewed in Ochs et al., 2005; Figure 1B).
Immunological and clinical similarities between IPEX in 
humans and autoimmunity/inflammation produced in rodents 
by Treg depletion prompted researchers to determine the 
possible role of Foxp3 in Treg development and function 
(Hori et al., 2003; Khattri et al., 2003; Fontenot et al., 2003). 
The studies revealed that CD25+CD4+ peripheral T cells 
and CD25+CD4+CD8− thymocytes in normal mice express 
Foxp3, whereas other thymocytes/T cells, either in a resting 
or activated state, do not. Ectopic retroviral transduction of 
the Foxp3 gene in CD25−CD4+ T cells can convert them to 
CD25+CD4+ Treg-like cells that are able to suppress prolif-
eration of other T cells in vitro and inhibit the development 
of autoimmune disease and inflammatory bowel disease in 
vivo (Hori et al., 2003). Foxp3 transduction in naive T cells 
also upregulates the expression of CD25 and other Treg-
associated cell-surface molecules, such as cytotoxic T cell-
associated antigen-4 (CTLA-4) and glucocorticoid-induced 
TNF receptor family-related gene/protein (GITR), whereas it 
represses the production of IL-2, IFN-γ, and IL-4. Both Foxp3-
deficient mice and Scurfy mice, whose Foxp3 protein lacks the 
forkhead domain, harbor few CD25+CD4+ Tregs, and inocula-
tion of CD25+CD4+ T cells from normal mice prevents severe 
systemic inflammation in Scurfy mice (Fontenot et al., 2003). 
In bone marrow chimera with a mixture of cells from wild-type 
and Foxp3-deficient mice, Foxp3-deficient bone marrow cells 
failed to give rise to CD25+CD4+ Tregs, whereas Foxp3-intact 
bone marrow cells generated Tregs that suppressed disease 
development. Conversely, in transgenic mice that overex-
press Foxp3, the number of CD25+CD4+ T cells is enhanced; 
CD25−CD4+ T cells and CD8+ T cells expressed high levels of 
Foxp3 and exerted suppression in vitro (Khattri et al., 2003). 
Recent analyses reveal that Foxp3-expressing T cells appear 
shortly after birth and show that the development of autoim-
mune/inflammatory disease follows their depletion (Kim et al., 
2007; Lahl et al., 2007).
Thus, the transcription factor Foxp3 is critical for α/β TCR-
positive T cells to differentiate to Tregs in the thymus (Fig-
ure 1C). High-level expression of Foxp3 is sufficient to confer 
suppressive activity to normal non-Treg cells. Further, genetic 
disruption of Foxp3 in humans and mice provides unequivo-
cal evidence that dominant self-tolerance is operating in 
both species (Figure 1B). Foxp3 is currently the most reliable 
molecular marker for natural Tregs and provides clues with 
which to decipher the molecular and genetic basis of Treg 
development and function.
Interleukin 2 Maintains Foxp3+ Tregs
Interleukin 2 (IL-2) is another molecule critical for the function 
of Tregs. The Treg marker CD25 is a component of the high-
affinity IL-2 receptor (IL-2R) and is functionally essential for Treg development. IL-2 has long been thought to be a major 
cytokine for T cell proliferation and differentiation based on 
its effects on T cell growth in vitro. It has therefore been puz-
zling that mice lacking IL-2 do not exhibit serious defects in 
T cell differentiation and function. Instead, these mice spon-
taneously develop T cell-mediated fatal lymphoproliferative/
inflammatory disease with autoimmune components (such as 
hemolytic anemia and lymphocytic infiltration into multiple 
organs) and hyperreactivity to commensal microbes (reviewed 
in Malek and Bayer, 2004). Mice deficient in CD25 or CD122 
(another component of the IL-2R) also succumb to a similar 
set of ailments, generally called IL-2 deficiency syndrome. In 
humans, CD25 deficiency, which accompanies severe auto-
immunity and allergy, is indistinguishable from IPEX (Caudy 
et al., 2007). Evidence suggests that the syndrome is due to 
deficiency or dysfunction of Foxp3+ Tregs. First, the number 
of Foxp3+ Tregs is reduced in mice lacking either CD25 or 
IL-2 (Antony et al., 2006), and autoimmunity in CD25-deficient 
mice can be prevented by inoculating them with wild-type 
CD25+CD4+ T cells (reviewed in Malek and Bayer, 2004). Sec-
ond, T cell-specific deficiency of STAT5a and b, which mediate 
signaling from the IL-2R β chain to the nucleus, abrogates the 
development of Foxp3+ Tregs, producing autoimmune/inflam-
matory disease (Burchill et al., 2007; Yao et al., 2007). Third, 
administration of a high dose of neutralizing anti-IL-2 mono-
clonal antibody to normal neonatal mice substantially reduces 
the number of Foxp3+CD25+CD4+ T cells for a limited period 
and elicits autoimmune diseases similar to those produced 
by Treg depletion (Setoguchi et al., 2005). In addition, IL-2 is 
required for sustained expression of Foxp3 and CD25 in natu-
ral Tregs and enhances their suppressive function, at least in 
vitro (Fontenot et al., 2005; Shevach et al., 2006). Although 
other γc cytokines also contribute to Treg development and 
maintenance, they are unable to fully replace the roles of IL-2 
or prevent IL-2 deficiency syndrome. For example, in contrast 
with mild reduction of Foxp3+ cells in mice lacking either IL-2 
or CD25, deficiency of CD122 (shared by IL-2R and IL-15R) 
or CD132 (shared by IL-2R, IL-4R, IL-7R, IL-9R, IL-21R, and 
IL-15R),or double deficiency of IL-2 and IL-15 lead to a pro-
found reduction in the number of Tregs (Fontenot et al., 2005; 
Burchill et al., 2007). Yet, deficiency of IL-4, IL-7, or IL-15 alone 
does not alter the number of Foxp3+ cells or produce autoim-
munity. Thus, IL-2 is vital and irreplaceable for the develop-
ment, survival, and function of Foxp3+ natural Tregs.
It is well known that IL-2 has multiple targets, including CD4+ 
and CD8+ T cells, B cells, and natural killer cells, and exerts 
pleiotropic functions with apparently contradictory effects on 
immune responses. It facilitates differentiation of CD4+ T cells 
to Th1 and Th2 cells and expands CD8+ memory T cells and 
natural killer cells. On the other hand, IL-2 promotes apoptosis 
in antigen-activated T cells. IL-2 also maintains Foxp3+ natu-
ral Tregs, expands them at high doses, and facilitates TGF-β-
dependent differentiation of naive T cells to Foxp3+ Tregs, but 
inhibits TGF-β/IL-6-dependent differentiation of naive T cells to 
inflammatory Th17 cells (Laurence et al., 2007). Thus, assum-
ing that the main source of IL-2 is activated T cells, there is a 
negative feedback control of immune responses via IL-2; that 
is, IL-2 produced by activated nonregulatory T cells contributes Cell 133, May 30, 2008 ©2008 Elsevier Inc. 777
to the maintenance, expansion, and activation of natural Tregs, 
which in turn limits the expansion of nonregulatory T cells (Fig-
ure 2). Disruption of this IL-2-mediated feedback loop at any 
step promotes the development of autoimmune/inflammatory 
disease. Further, manipulation of this feedback loop is instru-
mental in tuning the intensity of Treg-mediated suppression, 
hence the strength of a variety of immune responses.
Control of Treg Function by Foxp3
How does Foxp3 orchestrate the cellular and molecular programs 
involved in Treg function? It has been shown that Foxp3, which 
appears to operate as a homo-oligomer, interacts with the tran-
scription factors NFAT (nuclear factor of activated T cells), AML1 
(acute myeloid leukemia-1)/Runx1 (runt-related transcription fac-
tor 1), the histone acetyl transferase (HAT)/histone deacetyl trans-
ferase (HDAC) complex, and possibly NF-κB (Figure 3A).
The activity of NFAT is controlled by calcium and the 
calcium-dependent protein phosphatase calcineurin. Upon 
activation, NFAT forms a complex with AP-1 and NF-kB and 
promotes the expression of Il2, Il4, Ctla4, and other genes 
in conventional T cells, thus contributing to the activation of 
T cells and their differentiation to effector T cells (reviewed 
in Rao et al., 1997). A recent study has shown that the inter-
action between Foxp3 and NFAT is dependent upon their 
cooperative binding to DNA (Wu et al., 2006). Amino acid 
substitutions in the forkhead domain of Foxp3 that disrupt 
the Foxp3-NFAT interaction impair the ability of Foxp3 to 
repress Il2, activate Ctla4 and Cd25, and confer suppres-
sive activity when expressed in normal T cells. Although four 
known types of NFAT may function redundantly, mice defi-
cient in both NFATc2 and NFATc3 spontaneously develop 
severe lymphoadenopathy and selective activation of Th2 
cells accompanying hyperproduction of IgE, suggesting that 
the deficiency might disrupt the function of Foxp3 and con-
sequently impair Treg function (Ranger et al., 1998).
Figure 2. Key Roles of IL-2 in Immune Homeostasis
Interactions among Tregs, non-Treg cells, and antigen-presenting cells (APC) and 
feedback control of Treg function via IL-2. Foxp3, together with other transcrip-
tion factors and coactivators/corepressors, represses the transcription of IL-2 in 
Tregs, rendering them highly dependent on exogenous IL-2 (mainly produced by 
activated non-Treg cells) for their maintenance and function. Foxp3 also activates 
the genes encoding Treg-associated molecules such as CD25, CTLA-4, and 
GITR and confers suppressive activity to Tregs, which directly suppress non-Treg 
cells or modulate the function of APC to activate non-Treg cells.778 Cell 133, May 30, 2008 ©2008 Elsevier Inc.AML1/Runx1 is crucial for normal hematopoiesis includ-
ing thymic T cell development (Taniuchi et al., 2002). It is 
expressed in conventional T cells and to a slightly lesser 
degree in natural Tregs (Ono et al., 2007). In contrast with 
NFAT, which is dephosphorylated by calcineulin and translo-
cates from the cytoplasm to the nucleus upon T cell activa-
tion, AML1/Runx1 may constitutively bind to the Il2 promoter 
at the site upstream to the binding sites of NFAT, AP-1, and 
NF-kB. Upon T cell activation, it may act as an organizing 
factor that facilitates the assembly of transcriptional activa-
tion complexes containing NFAT on the Il2 promoter. Alter-
natively, AML1/Runx1, alone or together with its interact-
ing partners such as p300 and CREB-binding protein, may 
cooperate with the NFAT transcription complex to activate 
the Il2 promoter. In contrast, in Tregs, AML1/Runx1 physi-
cally binds to Foxp3 at its N-terminal region between the 
leucine zipper domain and the forkhead box (Figure 3A). Dis-
rupting the binding between Foxp3 and AML1/Runx1 impairs 
the Foxp3-dependent suppression of IL-2 production and 
attenuates suppressive activity without affecting the bind-
ing of Foxp3 to NFAT. Knockdown of AML1/Runx1 in natural 
Tregs abrogates their suppressive activity. Further, Treg-
specific disruption of the AML1/Runx1 gene in mice affects 
Foxp3 function and causes autoimmune disease similar to 
that produced by Treg depletion (A. Kitoh, M.O., and S.S., 
unpublished data).
Transcriptional control exerted by Foxp3 also involves HATs, 
such as TIP60, and HDACs, such as HDAC7 and HDAC9 (Li 
and Greene, 2007) (Figure 3A). Acetylation of Foxp3 by TIP60 
enhances the binding of Foxp3 to the Il2 promoter and aug-
ments the repression of Il2 (Chen et al., 2006). It remains to 
be determined how the interaction of Foxp3 with coactivators 
and corepressors modifies the function of NFAT and AML1/
Runx1 and controls the expression of Foxp3 target genes 
including Il2, Cd25, Ctla4, and Gitr.
Another approach to understanding how Foxp3 controls 
Treg function is to identify Foxp3 target genes genomewide. 
Transcriptome analysis has revealed several genes, such 
as those encoding G protein-coupled receptor 83 (Gpr83) 
or Extracellular matrix 1 (Ecm1), that are predominantly 
expressed in natural Tregs and Foxp3-transduced T cells. 
Other genes, such as those encoding Granzyme B and the 
transcription factor Helios, are highly specific to Tregs but 
are apparently expressed independently of Foxp3 (Fontenot 
et al., 2005; Sugimoto et al., 2006; Hill et al., 2007). Retroviral 
transduction of either group of genes in CD25−CD4+ T cells 
failed to confer suppressive activity in vitro (Sugimoto et al., 
2006).
Recent searches for Foxp3 target genes have shown 
that Foxp3 directly or indirectly controls hundreds (~700) of 
genes and binds directly to ~10% of them (Marson et al., 
2007; Zheng et al., 2007). Foxp3-binding genes include those 
encoding signal transduction molecules (such as Zap70 and 
Ptpn22), transcription factors (such as Crem), cytokines (e.g., 
Il2), cell-surface molecules (such as Il2ra, Ctla4, and FasL), 
enzymes for cell metabolism (such as Pde3b), and intergenic 
microRNAs (such as miR-155). microRNAs do indeed appear 
to play an important role in Treg development. T cell-specific 
depletion of Dicer, an RNase enzyme required for process-
ing double-stranded RNA, hampers thymic development of 
Foxp3+ T cells and elicits inflammatory bowel disease (Cobb 
et al., 2006). Altogether, these genomewide studies clearly 
show that Foxp3 functions as an activator as well as a repres-
sor of transcription depending on the target.
Taken together, the characterization of Foxp3 interacting 
partners and Foxp3 target genes has revealed that Foxp3 
interacts with transcription factors (such as NFAT and AML1/
Runx1) that otherwise facilitate the activation of non-Treg cells 
and their differentiation into effector T cells. This suggests a 
model of Foxp3 function, in which Foxp3 overrides or hijacks 
the transcription machinery for effector T cells, thereby func-
tionally converting them to Tregs (Figure 3B). Supporting this 
model, in mice genetically engineered to express a substan-
tially lower amount of Foxp3 than normal, natural Tregs not 
only lose suppressive activity but also spontaneously differ-
entiate to effector T cells that secrete IL-2, IFN-γ, and IL-4 
(Wan and Flavell, 2007). Furthermore, Foxp3 may interact with 
RORγt, a key transcription factor for the differentiation of naive 
T cells to Th17 cells, and thereby inhibit Th17 differentiation 
(Bettelli et al., 2006, and see below). It remains an open ques-
tion as to how the Foxp3 complex containing NFAT and AML1/
Runx1 (together with HATs and HDACs) controls the genes 
that mediate suppression. In addition, the existence of genes 
that are highly Treg specific but Foxp3 independent suggests 
that there might be a higher level of transcriptional regulation 
upstream of Foxp3 or coregulation of Treg differentiation and 
function with other transcription factors.
The Antigen Recognition Repertoire of Tregs
A cardinal feature of Foxp3+ natural Tregs is that unlike the 
majority of thymus-produced naive T cells, they are already 
functionally mature (that is, competent to prevent autoim-
mune disease and exert suppression in vitro) and “antigen-
primed” in the thymus, before encountering antigen in the 
periphery (Sakaguchi et al., 1982; Itoh et al., 1999). Foxp3+ 
thymocytes are detectable from a late CD4+CD8+ stage to 
the CD4- or CD8-single positive stage, constituting ~5% of 
mature CD4+CD8− thymocytes and less than 1% of CD4−CD8+ 
thymocytes (Fontenot et al., 2005) (Fig-
ure 4A). Only a small fraction of Foxp3+ 
thymocytes develop in mice deficient in 
the class I and II (MHC) histocompat-
ibility complex, indicating that Foxp3+ 
thymocytes or their Foxp3− precur-
sors are subjected to positive and negative selection in the 
thymus through interactions with self-peptide/MHC ligands 
expressed by thymic stromal cells.
How then do thymocytes differentiate into functional Foxp3+ 
Tregs through the thymic selection process? Evidence sug-
gests that natural Tregs may possess TCRs with higher affin-
ity for thymic MHC/self-peptide ligands than those of other 
T cells, and that such highly self-reactive T cells would be 
recruited to the Treg cell lineage in the course of thymic T 
cell selection. First, in double-transgenic mice expressing a 
transgene-encoded peptide (e.g., an ovalbumin peptide) in 
the thymic stromal cells at a high level, the majority of T cells 
expressing transgenic α and β chains specific for the peptide 
differentiate to CD25+CD4+ Tregs (Jordan et al., 2001; Kawa-
hata et al., 2002). In contrast, Tregs fail to develop when dou-
ble-transgenic mice express either a low-affinity transgenic 
TCR or a high concentration of the peptide, presumably due 
to insufficient positive selection or strong negative selection, 
respectively. This apparently high self-reactivity of Foxp3+ 
cells could be a consequence of positive selection of highly 
self-reactive T cells to the Treg lineage or a resistance of dif-
ferentiated Foxp3+ cells to negative selection (van Santen et 
al., 2004). Second, in TCR transgenic mice, which spontane-
ously develop CD25+CD4+ Tregs in an equivalent number as 
in nontransgenic mice, Tregs predominantly express endog-
enous TCR α chains paired with the transgenic β chain. In 
contrast, the majority of CD25−CD4+ T cells express the TCR 
solely composed of transgenic α and β chains (Itoh et al., 
1999). RAG deficiency, which blocks gene arrangement at the 
endogenous TCR α chain locus, abrogates the development 
of CD25+CD4+ Tregs in TCR transgenic mice, indicating that 
self-reactive TCRs utilizing endogenous α chains may con-
tribute to the positive selection of thymocytes to Tregs. The 
lack of Tregs due to RAG deficiency exacerbates autoimmune 
disease in mice expressing autoimmune transgenic TCRs. 
Third, a mutation in the gene encoding LAT (linker of acti-
vated T cell), a TCR proximal signal transduction molecule, 
abolishes the generation of Foxp3+ Tregs in the thymus and 
periphery while allowing the development of other T cells. 
This indicates that Treg development requires a strong signal 
Figure 3. Control of Treg Function by Foxp3
(A) The structure of the transcription factor Foxp3. 
Bars indicate the binding sites for other transcrip-
tion factors or chromatin-remodeling enzymes. 
Pro: Proline-rich region, ZnF: zinc finger domain, 
LZ: leucine zipper domain, FHD: forkhead box. 
(B) The transcriptional complexes involving NFAT 
and AML1/Runx1 activate or repress the genes 
encoding cytokines and several cell-surface mol-
ecules in Treg and non-Tregs, depending on the 
presence of Foxp3.Cell 133, May 30, 2008 ©2008 Elsevier Inc. 779
Figure 4. Thymic Development of Foxp3+ Cells
(A) The composition of Foxp3+ cells in each thymocyte subpopulation is shown as a percentage. In the periphery, CD4+ non-Treg cells can differentiate to Foxp3+ 
Tregs under certain conditions. 
(B) Development of Foxp3+ Tregs in the thymus involves interaction with thymic stromal cells via various molecules. Foxp3− thymocytes at a late CD4+CD8+ or an 
early CD4+CD8− stage turn on a Treg differentiation program when they receive signals produced by the interaction between their TCRs and MHC/self-peptide 
complexes on thymic stromal cells, between their accessory molecules (e.g., CD28) and their ligands (e.g., CD80 and CD86), and/or via stromal cell-derived 
humoral factors (e.g., cytokines). Foxp3 expression following cell fate determination confers suppressive activity and stabilizes Treg function and phenotype 
(e.g., CD25 expression). Blue indicates that the thymocyte has a suppressive function (Sup+).via the TCR in the thymus (Koonpaew et al., 2006). Further-
more, in TCRβ-fixed transgenic mice with a single copy of the 
TCRα locus or a “mini-TCRα” transgenic locus (which inhib-
its the appearance of T cells expressing double α chains), 
sequence analyses of TCR Vα segments of a particular Vα 
subfamily in CD25+ or CD25−CD4+ T cells have revealed dis-
tinct repertoires of the two populations, although the degree 
of overlap needs to be assessed more precisely (Hsieh et al., 
2006; Pacholczyk et al., 2007).
In addition to the affinity of the interaction between the 
TCR and self-peptide/MHC, the intensity of the interaction 
between T cell accessory molecules and their ligands on 
thymic stromal cells contributes to the generation of natu-
ral Tregs. For example, deficiency of CD28, CD40, CD11a/
CD18 (LFA1), or CD80 and CD86 (B7) results in a substantial 
reduction of CD25+CD4+ Tregs in the thymus and periphery 
(reviewed in Sakaguchi, 2005).
At the cellular level, both medullary thymic epithelial cells 
(mTECs) and dendritic cells in the thymus contribute to Treg 
generation as well as negative selection of naive T cells. 
Deficiency in the tumor necrosis factor receptor-associated 
factor 6 (TRAF6) or NF-κB-inducing kinase results in the 
absence of mature mTECs, hampering the development of 
Tregs (Akiyama et al., 2005; Kajiura et al., 2004). In humans, 
the cytokine TSLP (thymic stromal lymphopoietin) secreted 
by Hassal’s corpuscles, which are derived from mTECs, 
appears to act on thymic dendritic cells to promote the dif-
ferentiation of thymocytes to Tregs (Watanabe et al., 2005). A 
population of mTECs ectopically express a set of tissue-spe-
cific antigens (TSAs), such as insulin, under direct or indirect 
control of the gene Aire (autoimmune regulator) (reviewed in 
Mathis and Benoist, 2007). Interestingly, Aire-deficient mice 
spontaneously develop autoimmune diseases similar to those 
produced by Treg depletion. A recent study has suggested 
that Aire+ mTECs expressing TSAs may induce or facilitate 
the development of TSA-specific Tregs in normal thymus, 
and that a paucity of TSA-specific Tregs may contribute to 780 Cell 133, May 30, 2008 ©2008 Elsevier Inc.the occurrence of autoimmune disease in Aire deficiency 
(Aschenbrenner et al., 2007).
Thus, the avidity of interaction between thymocytes and 
stromal cells is critical in determining the fate of developing 
thymocytes to the Treg lineage. Interestingly, recent stud-
ies suggest that Foxp3 per se is not required for this initial 
cell fate determination in the thymus (Lin et al., 2007; Gavin 
et al., 2007). In mice in which the Foxp3 encoding region is 
replaced by a green fluorescent protein (GFP) reporter, GFP-
positive thymocytes, which do not express the Foxp3 pro-
tein, exhibit some elements of the Treg phenotype (including 
the expression of Treg-associated cell-surface molecules, 
such as CD25), although they are not suppressive in vitro. 
This indicates that the interaction of developing thymocytes 
with thymic stromal cells turns on a program of transcrip-
tional regulation in parallel with or upstream of Foxp3, and 
that once the Foxp3 gene is switched on, Foxp3 may sta-
bilize and sustain the Treg phenotype and confer suppres-
sive activity. Future efforts will examine how spatiotemporal 
interactions between thymocytes and stromal cells turn on 
the Treg differentiation program in developing thymocytes. 
Specifically, it needs to be determined whether the inten-
sity of signaling via the TCR and accessory molecules alone 
is sufficient for cell fate determination to the Treg lineage 
or whether stromal cell-derived humoral factor(s) including 
cytokines are also required. It is also unclear how the inter-
action evokes Foxp3 expression in Treg-committed thymo-
cytes (Figure 4B).
Peripheral Generation of Tregs from Naive T Cells
Naive T cells in the periphery can also acquire Foxp3 expres-
sion and consequently Treg function in several experimental 
settings, for example, in vitro antigenic stimulation of naive 
T cells in the presence of TGF-β (Chen et al., 2003; Apos-
tolou and von Boehmer, 2004; Kretschmer et al., 2005). In 
TGF-β-dependent in vitro Treg induction, IL-6 hampers the 
differentiation of naive T cells to Foxp3+ cells (Bettelli et al., 
2006). Interestingly, TGF-β stimulation in the presence of IL-6 
facilitates T cell differentiation to Th17 cells in mice (Veldhoen 
et al., 2006; Bettelli et al., 2006). IL-2 facilitates the differentia-
tion of naive CD4+ T cells into Foxp3+ Tregs but inhibits their 
differentiation into Th17 cells (Laurence et al., 2007). Addition-
ally, retinoic acid, which is secreted by a particular subset of 
dendritic cells in the gut-associated lymphoid tissue, inhibits 
IL-6-driven induction of Th17 cells. In the presence of TGF-β, 
retinoic acid facilitates the differentiation of naive T cells to 
Foxp3+ Tregs (Benson et al., 2007; Mucida et al., 2007; Sun et 
al., 2007; Coombes et al., 2007). Hence, orally administered 
protein antigens presented by retinoic acid-producing den-
dritic cells in the gut-associated lymphoid tissue may induce 
Foxp3+ Tregs. This could be a plausible mechanism of oral 
tolerance (Figure 5).
Yet, it remains to be determined whether Tregs induced from 
naive T cells in the periphery are functionally stable in vivo 
and to what extent they contribute to the peripheral pool of 
Foxp3+ Tregs (Figure 4A). For example, in mice the regulatory 
regions of the Foxp3 gene are more widely demethylated in 
natural Tregs than in TGF-β-induced Tregs, suggesting func-
tional instability of the latter (Floess et al., 2007). In addition, 
unlike mice, naive T cells in humans readily express Foxp3 
upon TCR stimulation, although the expression is generally 
much lower and more transient than in natural Tregs (Yagi et 
al., 2004; Gavin et al., 2006). Assuming that Foxp3 can sup-
press possible effector programs in T cells, it is an intriguing 
question whether Foxp3 not only confers suppressive func-
tion to natural Tregs but also may serve as an intrinsic brake 
to the further activation of antigen-stimulated effector T cells 
in humans.
Besides Foxp3+ Tregs, there are other types of Treg cells 
that can be induced from naive T cells in the periphery; for 
instance, CD4+ T cells secreting IL-10 and TGF-β, called Tr1 
cells, are produced in vitro by antigenic stimulation of naive T 
cells in the presence of IL-10 (Chen et al., 1994; Groux et al., 
1997). Antigen-specific TGF-β-secreting T cells, called Th3 
cells, were originally propagated from animals that became 
tolerant to orally administered protein antigen. At least some 
Th3 cells appear to be TGF-β-induced Foxp3+ Tregs. Tr1 cells 
do not express Foxp3, yet their properties in vitro are very 
similar to those of Foxp3+ Tregs. For example, they exhibit 
diminished proliferation in response to antigenic stimulation, 
exert cell contact-dependent suppression, scarcely produce 
IL-2, and display an activated cell-surface phenotype (Vie-
ira et al., 2004). It is likely that Tr1 and natural Foxp3+ Tregs 
may share some common suppressive mechanims in vitro, 
although long-term stability of Tr1 and Th3 cells needs to be 
further assessed in vivo.
A variety of other T cell subpopulations including CD8+, 
CD4−CD8−, and γ/δ T cells have also been reported to exhibit 
an immunosuppressive activity (reviewed in Shevach, 2006). 
There is so far little evidence that they play crucial roles in 
natural self-tolerance. CD8+ suppressor T cells were widely 
and intensively studied in the 1970s but have defied precise 
molecular characterization. These cells may now need to be 
recharacterized with currently available molecular tools. It is 
noteworthy that antigen immunization with strong adjuvant expands not only CD4+Foxp3+ T cells but also CD8+Foxp3+ 
T cells from a number that is negligible in unimmunized mice 
(Haribhai et al., 2007). These cells could plausibly correspond 
to some of the antigen-induced CD8+ suppressor T cells pre-
viously described (Cantor et al., 1976).
Trafficking and Localization of Tregs
Where are Foxp3+ natural Tregs found in the body? Dendritic 
cells in the draining lymph nodes present tissue-specific self-
antigens (Scheinecker et al., 2002), and Foxp3+ Tregs specific 
for tissue self-antigens are enriched in the regional lymph 
nodes (Samy et al., 2005). This indicates that antigen-spe-
cific Tregs migrate to and become activated in regional lymph 
nodes where tissue-specific self-antigens or microbial anti-
gens are presented. They also migrate into inflamed tissues, 
infectious sites, and tumors (Belkaid et al., 2002). In addi-
tion to TCRs that recognize specific antigens, Foxp3+ Tregs 
express a spectrum of homing receptors, including adhesion 
molecules and chemokine receptors (Huehn and Hamann, 
2005). In the peripheral lymph nodes, the majority (~80%) of 
Foxp3+ Tregs express CCR7 at high levels. Foxp3+ Tregs are 
slightly higher than Foxp3− T cells in the expression of CCR4, 
CCR6, CXCR4, and CXCR5. A fraction (~30%) of Foxp3+ 
Tregs express CD103 (integrin αEβ7), which interacts with its 
ligand E-cadherin expressed by epithelial cells; a substan-
tial fraction (~50%) highly express CD62L (L-selection), which 
interacts with the vascular addressins CD34, GlyCAM-1, 
and MAdCAM-1 expressed by the endothelium in lymph 
nodes and mucosal lymphoid tissue (reviewed in Huehn and 
Hamann, 2005). The expression of these homing receptors 
Figure 5. Differentiation of Naive CD4+ T Cells into Tregs or Effector 
T Cells 
Cytokines and transcription factors that promote the differentiation of naive 
T cells into Tregs or effector T cells are shown. The transcription factors T-
bet and Runx3, GATA3, or RORγt are required for the differentiation of naive 
T cells into Th1, Th2, or Th17 cells, respectively. nTreg, natural Treg; iTreg, 
induced Treg; RA, retinoic acid.Cell 133, May 30, 2008 ©2008 Elsevier Inc. 781
Figure 6. Possible Mechanisms of Treg-
Mediated Suppression
More than one mechanism of Treg-mediated 
suppression may operate for the control of a 
particular immune response in a synergistic and 
sequential manner. Antigen-activated Tregs are 
recruited to antigen-presenting cells (APCs), es-
pecially dendritic cells (DCs), and out-compete 
antigen-specific naive T cells regarding interac-
tions with dendritic cells mainly because of the 
high expression of adhesion molecules (such as 
LFA-1) by Tregs. Tregs then modulate dendritic 
cell function. For example, Tregs promote the downregulation of dendritic cell CD80 and CD86 by a CTLA-4-dependent mechanism. Some Tregs may 
further differentiate to kill or inactivate responder T cells by secreting granzyme/perforin or immunosuppressive cytokines (such as IL-10).in Tregs controls their trafficking and localization and conse-
quently the compartmentalization of Treg-controlled immune 
responses.
The expression patterns of homing receptors correlate with 
the functional heterogeneity of Tregs. CCR7+CD62Lhigh Tregs, 
which migrate to the secondary lymphoid tissues, have an 
enhanced capacity to prevent the development of autoimmune 
diabetes in a mouse model, suggesting suppression of self-re-
active T cells in the regional lymph nodes (Szanya et al., 2002). 
Foxp3+ Tregs that express CD103 are memory-like and more 
suppressive than CD103− Tregs in vitro and in vivo. In a murine 
colitis model, Foxp3+ Tregs that express CD103 are able to 
control colitis in the colonic mucosa (Uhlig et al., 2006). Simi-
larly, CCR5+ Tregs preferentially migrate to cutaneous lesions 
of Leishmania major infection (Yurchenko et al., 2006).
The expression patterns of homing receptors are basically 
similar to those of effector T cells migrating to the same tis-
sue site. CCR4+ Tregs as well as CCR4+ effector T cells accu-
mulate in inflamed skin following local antigen inoculation 
(Sather et al., 2007). CCR6+ Tregs and CCR6+ Th17 cells are 
both elevated in inflamed joints in an animal model of rheu-
matoid arthritis (Hirota et al., 2007). Additionally, retinoic acid 
secreted by intestinal CD103+ dendritic cells induces gut-
homing integrin α4β7 in Tregs and non-Treg cells.
Treg-specific deficiency of a particular homing receptor or 
its blockade compromises Treg function, for example, in the 
control of tissue-localized inflammation, local maintenance 
of allograft tolerance, and fetomaternal tolerance (Lee et al., 
2005; Yurchenko et al., 2006; Schneider et al., 2007; Sather 
et al., 2007; Kallikourdis et al., 2007). Thus, migration recep-
tors on Tregs are highly informative in assessing Treg behav-
ior in vivo and can be exploited to control immune responses 
through altering Treg trafficking and localization.
Treg Activation, Proliferation, and Differentiation
Upon antigen exposure in the regional lymph nodes, Foxp3+ 
Tregs become activated and exert suppression at a much lower 
concentration of antigen than naive T cells. In TCR transgenic 
mice, the concentration of peptide required to activate the 
peptide-specific Tregs to exert suppression in vitro has been 
estimated to be 10- to 100-fold lower than the concentration 
needed for activating naive T cells with the same antigen speci-
ficity (Takahashi et al., 1998). This finding suggests that natural 
Tregs can be activated even by immature dendritic cells whose 
expression levels of CD80/86 and self-peptide/MHC are too low 
to activate naive self-reactive T cells. This might enable natural 782 Cell 133, May 30, 2008 ©2008 Elsevier Inc.Tregs to exert dominant and tonic suppression of self-reactive T 
cells. It could also contribute to the prevention of autoimmunity 
stemming from molecular mimicry (the antigenic crossreaction 
between a self-molecule and a microbial substance) because 
natural Tregs could be more easily activated than self-reactive T 
cells by such a substance (Stephens et al., 2005).
Notably, unlike their hypoproliferation upon antigenic stimulation 
in vitro, a sizable fraction of Foxp3+ natural Tregs are continuously 
proliferating in vivo presumably through the recognition of self-
antigen and commensal microbes (Fisson et al., 2003; Setoguchi 
et al., 2005). Natural Tregs can also expand clonally in vivo and in 
vitro following antigenic stimulation and retain their suppressive 
function after expansion (Klein et al., 2003; Yamazaki et al., 2003; 
Fehérvári and Sakaguchi, 2004; Yamaguchi et al., 2007).
Various stimuli via accessory molecules expressed by 
Foxp3+ Tregs also lead to their expansion in vivo and in vitro. 
Stimulation of GITR, which is constitutively expressed in Tregs 
at a higher level than in other T cells, facilitates vigorous pro-
liferation of Tregs in the presence of IL-2 in vitro (McHugh et 
al., 2002; Shimizu et al., 2002). In addition, Tregs can expand 
following stimulation via Toll-like receptors (TLRs), indepen-
dent of TCR recognition of a specific antigen. Tregs respond 
to ligands for TLR2, 4, 5, and 8, including bacterial flagellin 
that acts through TLR5 (reviewed in Sutmuller et al., 2006). 
A similar effect is observed with 60 kDa heat shock protein, 
a self-molecule, with Pam3Cys via mouse TLR2, or with 
lipopolysaccharide via TLR4.
Irrespective of active proliferation the number of Foxp3+ 
natural Tregs is fairly constant in normal animals (10%–15% of 
CD4+ T cells), indicating that cell death helps to maintain Treg 
homeostasis. Indeed, following antigenic stimulation Tregs 
downregulate Bcl-2, an antiapoptotic protein (Yamaguchi et 
al., 2007). Further, among Foxp3+CD4+ T cells in humans, anti-
gen-stimulated naive Foxp3low cells differentiate into effector/
memory-like Foxp3high cells, which vigorously proliferate and 
then die (M. Miyara and S.S., unpublished data).
Thus, Foxp3+ Tregs that have migrated to lymphoid and 
nonlymphoid tissues become activated, proliferate, exert 
suppressive activity, and then die. However, it remains to 
be determined whether some Tregs further differentiate into 
long-lived memory-type cells.
Multiple Modes of Treg-Mediated Suppression?
A key issue of current research on Tregs is to understand the 
mechanism of Treg-mediated suppression. Foxp3+CD25+CD4+ 
natural Tregs suppress the proliferation of naive T cells and 
their differentiation to effector T cells in vivo. They can also 
suppress effector activities of differentiated CD4+ and CD8+ 
T cells and the function of natural killer cells, natural killer T 
cells, B cells, macrophages, osteoclasts, and dendritic cells 
(reviewed in von Boehmer, 2005; Shevach, 2006; Miyara and 
Sakaguchi, 2007; Tang and Bluestone, 2008). In vitro Tregs 
suppress the proliferation and cytokine production (in partic-
ular of IL-2) of responder T cells when the two populations are 
cocultured and stimulated by antigen in the presence of anti-
gen-presenting cells (APC) (Takahashi et al., 1998; Thornton 
and Shevach, 1998). Once activated by a particular antigen, 
Tregs can suppress responder T cells irrespective of whether 
they share antigen specificity with the Treg (Takahashi et al., 
1998).
Several mechanisms of Treg-mediated suppression have 
been proposed, and these include secretion by the Treg of 
immunosuppressive cytokines, cell-contact-dependent sup-
pression, and functional modification or killing of APC (Figure 
6). For example, IL-10 and TGF-β contribute to suppression of 
inflammatory bowel disease induced in mice by Treg deple-
tion (Read et al., 2000). Tregs coexpressing Foxp3 and IL-10 
at a single-cell level are indeed found in lamina propria of the 
intestine but not in the spleen (Uhlig et al., 2006; Maynard et 
al., 2007). TGF-β may act as a direct mediator of suppression, 
condition responder T cells to be sensitive to suppression, 
and/or maintain Foxp3 expression and suppressive activ-
ity in Tregs (reviewed in von Boehmer, 2005). A recent study 
has shown that Foxp3+ natural Tregs predominantly produce 
immunosuppressive IL-35, a new member of the IL-12 family 
(Collison et al., 2007).
Alternatively, absorption of cytokines by Tregs may induce 
apoptosis in responder T cells (Pandiyan et al., 2007). Tregs 
might also kill responder T cells or APC through cell-to-cell 
contact by a granzyme- or perforin-dependent mechanism, 
or through delivery of a negative signal to responder T cells. 
Possible negative signals include upregulation of intracellular 
cyclic AMP, which leads to inhibition of T cell proliferation and 
IL-2 production, or the generation of pericellular adenosine 
catalyzed by CD39 (ectonucleoside triphosphate diphos-
phohydrolase 1) and CD73 (ecto-5′-nucleotidase) expressed 
by Tregs (reviewed in Tang and Bluestone, 2008). Activated 
Tregs may also downmodulate CD80/86 expression on APC 
or stimulate dendritic cells to form the enzyme indoleamine 
2, 3-dioxygenase, which catabolizes the essential amino acid 
tryptophan to kynurenines that are toxic to T cells; both appear 
to be dependent on the expression of CTLA-4 by Tregs.
Taken together, these findings suggest a model of Treg-
mediated suppression: (1) upon antigenic stimulation, 
antigen-specific Tregs, which are highly mobile, are swiftly 
recruited via chemokines to dendritic cells presenting the 
antigen and out-compete antigen-specific naive T cells in 
aggregating around the dendritic cells; (2) antigen-activated 
Tregs contacting dendritic cells then downmodulate dendritic 
cell function, thereby hindering the activation of other T cells 
that are recruited to the dendritic cells; (3) Tregs may then 
further differentiate to secrete granzyme/perforin, IL-10, or 
other immunosupressive cytokines (such as IL-35) depend-
ing on the strength and duration of antigenic stimulation and the local milieu of cytokines and other substances (Figure 6). 
Consistent with this model, intravital imaging of Tregs and 
responder T cells in a lymph node by two-photon micros-
copy suggests that activated Tregs hamper stable contacts 
between responder T cells and antigen-presenting dendritic 
cells (Tang et al., 2006; Tadokoro et al., 2006). Assuming that 
in vivo activation of a naive T cell is a process that requires 
contact with an antigen-presenting dendritic cell for several 
hours (Celli et al., 2007), Treg-mediated interference may suf-
fice to render abortive the activation of responder T cells, 
thereby suppressing an immune response.
Deficiencies of some Treg-expressing molecules (such as 
LAG3, granzymes, and IL-35) can impair Treg suppression in 
vitro by affecting a particular mode of suppression but fail to 
cause autoimmunity in vivo because other modes may effec-
tively compensate for the deficiencies. Among the various 
molecules involved in suppression in vivo or in vitro, CTLA-4 
is critically important for the following reasons. Foxp3+ Tregs 
constitutively express CTLA-4, Foxp3 directly controls the 
expression of CTLA-4, and CTLA-4 blockade abrogates 
suppression. Further, not only germline deletion but also 
Treg-specific conditional deficiency of CTLA-4 induces fatal 
autoimmunity/inflammation in mice (Salomon et al., 2000; 
Read et al., 2000; Takahashi et al., 2000; K. Wing and S.S., 
unpublished data). Additional study is required to elucidate 
the molecular basis of suppression mediated by Tregs. The 
fate of responder T cells that are suppressed by Tregs is also 
unclear, that is, whether they remain nonactivated, die by 
apoptosis, or become anergic.
Tregs: A Clinical Perspective
To what extent are Treg anomalies responsible for immunolog-
ical diseases in humans and how might Tregs be exploited to 
control physiological and pathological immune responses?
Polymorphisms of several genes including Ctla4, Il2, Cd25, 
and Ptpn22 significantly contribute to genetic susceptibility 
to common autoimmune diseases, such as type I diabetes 
(Wellcome Trust Case Control Consortium, 2007). Deficiency 
of these genes, in particular Ctla4, Il2, and Cd25, produces 
severe autoimmunity in mice presumably through an effect 
on Treg development and function. Similarly, CTLA-4 block-
ade or IL-2 neutralization for a limited period elicits T cell-
mediated autoimmune disease in otherwise normal mice. It 
is therefore possible that the polymorphisms of these genes 
may alter Treg development or function and thereby render 
the host susceptible to autoimmune disease (Yamanouchi et 
al., 2007). Environmental factors might also affect Tregs and 
thereby contribute to the development of autoimmunity. Tregs 
display greater proliferation and higher metabolic activity than 
non-Tregs under physiological conditions. As a consequence, 
they are more sensitive to ionizing radiation, radiomimetic 
drugs (such as cyclophosphamide), and deficiency of certain 
vitamins such as folic acid (Fisson et al., 2003; Brode et al., 
2006; Setoguchi et al., 2005; Yamaguchi et al., 2007).
Although Treg depletion can evoke autoimmunity, it can 
also provoke and enhance tumor immunity in rodents (Shi-
mizu et al., 1999) (Figure 1). In vitro T cell responses against 
tumor-associated antigens are enhanced by stimulating T Cell 133, May 30, 2008 ©2008 Elsevier Inc. 783
cells from cancer patients (or even normal individuals) with 
tumor antigen after the depletion of natural Tregs (Danke et 
al., 2004; Nishikawa et al., 2005). In addition, Foxp3+ Tregs 
are abundant in tumors. Thus, natural Tregs that promote 
self-tolerance may act to impede immune surveillance 
against cancers in normal individuals and suppress poten-
tial responsiveness to autologous tumors in cancer patients. 
Targeting Tregs is a promising approach for cancer immu-
notherapy. Such approaches could include local depletion 
of Tregs in the tumor mass, attenuation of Treg function at 
the time of therapeutic vaccination with tumor antigen, and 
ex vivo expansion of tumor-infiltrating lymphocytes after the 
depletion of Tregs.
Similar to tumor immunity, depletion or reduction of natural 
Tregs enhances immune responses to pathogenic microbes 
(reviewed by Belkaid and Rouse, 2005). Yet, complete eradica-
tion of microbes via Treg depletion might hamper the devel-
opment of effective immunological memory for the microbes, 
thus impairing the secondary immune responses upon rein-
fection (Belkaid et al., 2002). Hence, Tregs control the quality 
and tune the magnitude of antimicrobial immune responses to 
protect the host from pathogenic microbes while avoiding col-
lateral immunopathology or inappropriate responses to com-
mensal microbes.
Foxp3+ natural Tregs retain their suppressive function 
after expansion in vivo and in vitro. By exploiting this stable 
suppressive activity and proliferative capacity, strategies 
that clonally expand antigen-specific natural Tregs while 
inhibiting the activation and expansion of effector T cells 
will help to induce transplantation tolerance and suppress 
graft rejection. Furthermore, in the presence of Tregs that 
actively maintain graft tolerance, naive T cells could be newly 
recruited to the graft site and could differentiate into graft-
specific Tregs, thereby augmenting graft tolerance (Wald-
mann et al., 2006). The same principle could be applied to 
the treatment of autoimmune disease, as well as allergy, and 
inflammatory diseases and might be used to augment feto-
maternal tolerance in pregnancy.
For the purpose of attenuating or enhancing Treg-me-
diated immune suppression in various clinical settings, it 
is necessary to find a specific molecular marker that can 
selectively and reliably differentiate between Tregs and 
effector T cells. Biologicals, such as monoclonal antibodies, 
and small molecules that have differential effects on Tregs 
and effector T cells may represent the next generation of 
therapeutic reagents to selectively suppress or enhance 
immune responses by controlling the balance between 
Tregs and effector T cells. Further elucidation of the cellular 
and molecular processes underlying the development and 
function of Tregs will help to establish new strategies for the 
treatment and prevention of immunological diseases and 
for the control of a wide spectrum of physiological immune 
responses.
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